Physician profile
Alan Williams
NPI 1215951439
$4,763.74
in general payments reported to CMS, 2019-2025
22 companies · $67.58 in 2025
The $67.58 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $314 · 2021: $1,005 · 2022: $1,093 · 2023: $1,024 · 2024: $488 · 2025: $67.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.35 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,032.55 | 2019-2024 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $932.31 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $620.11 | 2019-2023 | Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $433.09 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $342.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $220.68 | 2019-2023 | Dificid |
| Genzyme Corporation | $213.65 | 2022-2024 | |
| Celgene Corporation | $147.80 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $146.86 | 2022-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $107.12 | 2019-2024 | |
| Redhill Biopharma INC. | $102.49 | 2021-2022 | |
| Pfizer INC. | $89.75 | 2019-2024 | |
| Braintree Laboratories, INC. | $89.23 | 2019-2023 | Suflave |
| Ardelyx, INC. | $78.91 | 2022-2023 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $52.84 | 2023-2024 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.44 | 2024 | Voquezna |
| Alfasigma USA, INC. | $25.19 | 2020 | |
| Mauna Kea Technologies, INC. | $24.27 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.27 | 2021 | |
| Daiichi Sankyo INC. | $17.09 | 2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $16.00 | 2022 | |
| Lilly USA, LLC | $15.62 | 2024 | Zepbound, Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.